Comparison of pegaspargase with concurrent radiation vs.P-GEMOX with sequential radiation in early-stage NK/T-cell lymphoma  

作　　者：DEMEI FENG SHENRUI BAI GUANJUN CHEN BIBO FU CAILU SONG HAILIN TANG LIANG WANG HUA WANG 

机构地区：[1]State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou,510060,China [2]Department of Hematology,Beijing Tongren Hospital,Capital Medical University,Beijing,100730,China

出　　处：《Oncology Research》2025年第4期965-974,共10页肿瘤学研究(英文)

基　　金：funded by the National Natural Science Foundation of China grant 81700148 and Natural Science Foundation of Guangdong Province grant 2021A1515010093 and 2023A1515011862;funded by the National Natural Science Foundation of China grant 82170181;funded by the Basic and Applied Basic Research Foundation of Guangdong Province grant 2022B1515120087.

摘　　要：Objectives:The optimal treatment strategy for early-stage natural killer/T-cell lymphoma(NKTCL)remains unclear.This study aimed to evaluate and compare the clinical outcomes and adverse events(AEs)associated with two treatment regimens for early-stage NKTCL:pegaspargase with concurrent radiation therapy(P+CCRT)and pegaspargase,gemcitabine,and oxaliplatin(P-GEMOX)with sequential radiation therapy(SERT).Propensity score matching(PSM)was employed to ensure balanced comparison between these regimens.Methods:We assessed the efficacy of P+CCRT from a phase II trial and P-GEMOX combined with SERT using real-world data.PSM was conducted at a 1:1 ratio with a caliper of 0.18 to align baseline characteristics between the treatment groups.Key outcomes analyzed included overall response rate(ORR),complete response rate(CR),progression-free survival(PFS),overall survival(OS),and AEs.Results:Following PSM,the study included 52 patients,with 26 in each treatment group.Baseline characteristics were balanced between the cohorts.The ORR for P+CCRT group was 100.0%compared to 88.5%for P-GEMOX+SERT group,and the CR rates was 100.0%vs.76.9%,respectively.The 3-year OS and PFS rates were both 92.3%for P+CCRT,while P-GEMOX showed 92.3%OS and 80.8%PFS.Adverse events,including hematological toxicity,hepatotoxicity,and coagulation dysfunction,were comparable between the two regimens.Conclusion:P+CCRT is associated with comparable clinical outcomes compared to P-GEMOX+SERT in early-stage NKTCL,with comparable adverse events.Additionally,P+CCRT offers the benefit of a more streamlined treatment regimen with a shorter cycle.Given these encouraging results,further cohort studies are needed to validate these results.

关 键 词：Natural killer/T-cell lymphoma(NKTCL) Concurrent radiation therapy PEGASPARGASE Propensity score matching 

分 类 号：R733.1[医药卫生—肿瘤]